Glucocorticoids (GCs) are a central component of multi-drug treatment protocols against T
and B acute lymphoblastic leukemia (ALL), which are used intensively during the remission …

Background: BCR/ABL1-like acute lymphoblastic leukemia is a newly recognized high-risk
subtype of ALL, characterized by the presence of genetic alterations activating kinase and …

Resistance to glucocorticoids (GC) is associated with an increased risk of relapse in B-cell
progenitor acute lymphoblastic leukemia (BCP-ALL). Performing transcriptomic and single …

Although a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of
patients do not respond to conventional chemotherapy and experience disease relapse. A …

The ubiquitin-proteasome system is the crucial homeostatic mechanism responsible for the
degradation and turnover of proteins. As such, alterations at this level are often associated …

Philadelphia chromosome-like (Ph-like) ALL is a recent subtype of acute lymphoblastic
leukemia. Although it does not express the BCR-ABL fusion gene, it has a behavior like true …

A common finding in pediatric B‐cell precursor acute lymphoblastic leukemia (BCPALL) is
that chromosome 21 is never lost and an extra chromosome 21 is often gained. This implies …

Inflammation, a regulatory mechanism crucial for the homeostasis and maintenance of the
hematopoietic system, is capable of playing pathogenic roles that ultimately cooperate in …

Combining multiple drugs broadens the window of therapeutic opportunities and is crucial
for diseases that are currently lacking fully curative treatments. A powerful emerging tool for …

Abstract Purpose of Review Acute lymphoblastic leukemia (ALL) is a widely heterogeneous
disease in terms of genomic alterations, treatment options, and prognosis. While ALL is …